Thermal and X-ray powder diffraction structural characterization of two benfluorex hydrochloride polymorphs

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 1, 2010, Pages 1-6

  Maccaroni, Elisabetta ^a,b   Malpezzi, Luciana ^b   Panzeri, Walter ^c   Masciocchi, Norberto ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c CNR   (Italy)

Author keywords

Benfluorex hydrochloride; Structure determination; Thermal analysis; X ray powder diffraction

Indexed keywords

BENFLUOREX;

AB INITIO CALCULATION; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STABILITY; DRUG STRUCTURE; ENVIRONMENTAL TEMPERATURE; HYDROGEN BOND; MELTING POINT; PHASE TRANSITION; PRIORITY JOURNAL; STRUCTURE ANALYSIS; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DIFFERENTIAL THERMAL ANALYSIS; DRUG STABILITY; FENFLURAMINE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHASE TRANSITION; POWDER DIFFRACTION; X-RAY DIFFRACTION;

EID: 77952425005     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.02.037     Document Type: Article

References (17)

1. Hilfiker R. Polymorphism in the Pharmaceutical Industry 2006, Wiley-VCH.
2. Grant D.J.W. Polymorphism in Pharmaceutical Solids 1999, Marcel Dekker Inc., New York Basel, p. 1. H.G. Brittain (Ed.).
3. Di Martino P., Guyot-Hermann A.-M., Conflant P., Drache M., Guyot J.-C. A new pure paracetamol for direct compression: the orthorhombic form. Int. J. Pharm. 1996, 128:1-8.
4. Snider D.A., Addicks W., Owens W. Polymorphism in generic drug product development. Adv. Drug Del. Rev. 2004, 56:391-395.
5. Malpezzi L., Magnone G.A., Masciocchi N., Sironi A. Single crystal and powder diffraction characterization of three polymorphic forms of Acitretin. J. Pharm. Sci. 2005, 94:1067-1078.
6. Maccaroni E., Alberti E., Malpezzi L., Masciocchi N., Vladiskovic C. Polymorphism of linezolid: a combined single-crystal, powder diffraction and NMR study. Int. J. Pharm. 2008, 351:144-151.
7. Maccaroni E., Alberti E., Malpezzi L., Masciocchi N., Pellegatta C. Crystal chemistry of sibutramine: thermal, diffractometric and spectroscopic characterization. J. Pharm. Sci. 2008, 97:5229-5239.
8. 13C CPMAS NMR study of its anhydrous and solvated forms. Cryst. Growth Des. 2009, 9:517-524.
9. Maccaroni E., Malpezzi L., Masciocchi N. Structures from powders: bupropion hydrochloride. J. Pharm. Biomed. Anal. 2009, 50:257-261.
10. Scheen A.J. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003, 63:1165-1184.
11. L. Beregi, P. Hugon, J.-C. Le Douarec, Nouveaux dérivés du phényl-amino propane et leur procédé de préparation, FR1517587A, 1968.
12. European Pharmacopoeia 5.0, 1064.
13. TOPAS-R, Version 3.0, Bruker AXZ, Karlsruhe, Germany, 2005.
14. ChemSketch, Release 10.02, 2006, ACS/Labs., Toronto, Canada.
15. Grunewald G.L., Creese M.W., Extine M.W. Fenfluramine hydrochloride, (±)-N-ethyl-m-(trifluoromethyl)amphetamine hydrochloride. Acta Cryst. B 1981, 37:1790-1792.
16. Mayer M., Perez G., Petit M.N., Coquerel G. S(+)-2-ethylamino-1-(3-trifluoromethylphenyl)-propane hydrochloride. Cryst. Struct. Commun. 1982, 11:1853-1856.
17. W.I.F. David, K. Shankland, L.B. McCusker, Ch. Baerlocher (Eds.), Structure Determination from Powder Diffraction Data, Oxford University Press, Oxford, UK, 2002.